Key Takeaways
- • Boyd Street Capital launched HealthTech Platform Fund II with a $100 million target, positioning it as a growth capital vehicle for healthcare technology companies across AI, digital health, medical devices, diagnostics, and healthcare infrastructure sectors.
- • The fund represents a strategic expansion of Boyd Street Capital's Mission 2030 initiative, which aims to build a globally connected healthcare innovation ecosystem integrating growth capital, commercialization expertise, and strategic partnerships across research institutions and health systems.
- • Lisa Risser was appointed as General Partner of HealthTech Platform Fund II, tasked with leading investment strategy and commercialization initiatives across the portfolio.
- • The platform functions beyond traditional venture capital, serving as a commercialization hub designed to accelerate healthcare innovation translation from laboratory discovery through clinical adoption and global deployment.
Summary
Boyd Street Capital announced the establishment of HealthTech Platform Fund II on August 5, 2026, marking a significant milestone in the Oklahoma-based firm's healthcare innovation strategy. The fund targets $100 million in growth capital dedicated to investing in expansion-stage healthcare technology companies developing solutions across multiple segments including artificial intelligence, digital health platforms, medical devices, diagnostics, healthcare software, and healthcare infrastructure.
The fund launch forms a core component of Boyd Street Capital's Mission 2030 strategy, which extends beyond traditional venture capital structuring. Rather than operating as a standalone investment vehicle, HealthTech Platform Fund II functions as the growth capital engine within a broader integrated ecosystem. This ecosystem combines growth capital deployment, commercialization expertise, an in-house Venture Studio, and strategic partnerships spanning research institutions, health systems, industry participants, and capital providers. The stated objective is to create a unified commercialization platform designed to accelerate the translation of healthcare innovation from initial laboratory discovery through global clinical adoption.
In connection with the fund's launch, Boyd Street Capital appointed Lisa Risser as General Partner of HealthTech Platform Fund II. Risser will lead the fund's investment strategy and commercialization initiatives while interfacing directly with portfolio companies and strategic partners embedded within the healthcare ecosystem. The appointment signals the firm's commitment to combining capital deployment with active operational engagement across its healthcare portfolio.
The fund positioning reflects institutional demand for specialized growth capital in healthcare technology alongside strategic value-add services. By integrating capital, commercialization infrastructure, and network access within a single platform, Boyd Street Capital targets the identified gap between venture-stage funding and large-scale clinical and commercial deployment—a transition point where many promising healthcare innovations encounter execution and scaling challenges.
The fund launch forms a core component of Boyd Street Capital's Mission 2030 strategy, which extends beyond traditional venture capital structuring. Rather than operating as a standalone investment vehicle, HealthTech Platform Fund II functions as the growth capital engine within a broader integrated ecosystem. This ecosystem combines growth capital deployment, commercialization expertise, an in-house Venture Studio, and strategic partnerships spanning research institutions, health systems, industry participants, and capital providers. The stated objective is to create a unified commercialization platform designed to accelerate the translation of healthcare innovation from initial laboratory discovery through global clinical adoption.
In connection with the fund's launch, Boyd Street Capital appointed Lisa Risser as General Partner of HealthTech Platform Fund II. Risser will lead the fund's investment strategy and commercialization initiatives while interfacing directly with portfolio companies and strategic partners embedded within the healthcare ecosystem. The appointment signals the firm's commitment to combining capital deployment with active operational engagement across its healthcare portfolio.
The fund positioning reflects institutional demand for specialized growth capital in healthcare technology alongside strategic value-add services. By integrating capital, commercialization infrastructure, and network access within a single platform, Boyd Street Capital targets the identified gap between venture-stage funding and large-scale clinical and commercial deployment—a transition point where many promising healthcare innovations encounter execution and scaling challenges.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.